Maythinee Chantadisai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7990596/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using ¹⁷⁷ Lu-FAP-2286: First-in-Humans Results. Journal of Nuclear Medicine, 2022, 63, 415-423.	5.0	136
2	Whole-body uptake classification and prostate cancer staging in 68Ga-PSMA-11 PET/CT using dual-tracer learning. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 517-526.	6.4	23
3	MaligNet: Semisupervised Learning for Bone Lesion Instance Segmentation Using Bone Scintigraphy. IEEE Access, 2020, 8, 27047-27066.	4.2	22
4	Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20Âyears of experiences: prognostic parameters and overall survival. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1390-1398.	6.4	16
5	Effects of intradialytic cycling exercise on daily physical activity, physical fitness, body composition, and clinical parameters in high-volume online hemodiafiltration patients: a pilot randomized-controlled trial. International Urology and Nephrology, 2021, 53, 359-371.	1.4	16
6	Pretherapeutic Comparative Dosimetry of ¹⁷⁷ Lu-rhPSMA-7.3 and ¹⁷⁷ Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 2022, 63, 833-839.	5.0	13
7	Usefulness of 99mTc-pertechnetate whole body scan with neck and chest SPECT/CT for detection of post-surgical thyroid remnant and metastasis in differentiated thyroid cancer patients. Annals of Nuclear Medicine, 2014, 28, 674-682.	2.2	11
8	Positive predictive value and correct detection rate of ¹⁸ F-rhPSMA-7 PET in biochemically recurrent prostate cancer validated by composite reference standard. Journal of Nuclear Medicine, 2021, 62, jnumed.120.255661.	5.0	5
9	Comparison of the Diagnostic Performance of Myocardial Perfusion Scintigraphy with and Without Attenuation Correction. Molecular Imaging and Radionuclide Therapy, 2022, 31, 130-138.	0.7	3
10	Pharmacokinetic Modeling of ¹⁸ F-FDOPA PET in the Human Brain for Early Parkinson's Disease. Molecular Imaging and Radionuclide Therapy, 2021, 30, 69-78.	0.7	2
11	Impact of reconstruction parameters on lesion detection and localization in joint ictal/inter-ictal SPECT reconstruction. Annals of Nuclear Medicine, 2022, 36, 24-32.	2.2	2
12	Transthyretin Amyloidosis Mimicking Obstructive Hypertrophic Cardiomyopathy: A Great Imitator. Heart Lung and Circulation, 2019, 28, e108-e110.	0.4	1